Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Pericardial effusion after pediatric hematopoietic cell transplant.

Aldoss O, Gruenstein DH, Bass JL, Steinberger J, Zhang Y, Defor TE, Tolar J, Verneris MR, Orchard PJ.

Pediatr Transplant. 2013 May;17(3):294-9. doi: 10.1111/petr.12062. Epub 2013 Mar 7.

PMID:
23464863
3.

Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation.

Liu YC, Chien SH, Fan NW, Hu MH, Gau JP, Liu CJ, Yu YB, Liu CY, Hsiao LT, Liu JH, Chiou TJ, Tzeng CH.

Br J Haematol. 2015 Jun;169(5):737-45. doi: 10.1111/bjh.13357. Epub 2015 Mar 27.

PMID:
25818840
4.

Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation.

Dvorak CC, Steinbach WJ, Brown JM, Agarwal R.

Bone Marrow Transplant. 2005 Oct;36(7):621-9.

PMID:
16044133
5.

Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.

Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1587-95. doi: 10.1016/j.bbmt.2009.08.006. Epub 2009 Sep 30.

6.

Pericardial effusion post-SCT in pediatric recipients with signs and/or symptoms of cardiac disease.

Neier M, Jin Z, Kleinman C, Baldinger L, Bhatia M, Silver E, van de Ven C, Morris E, Satwani P, George D, Garvin J, Bradley MB, Schwartz J, Cairo MS.

Bone Marrow Transplant. 2011 Apr;46(4):529-38. doi: 10.1038/bmt.2010.149. Epub 2010 Jun 28.

PMID:
20581882
7.

Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.

Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ.

Biol Blood Marrow Transplant. 2009 May;15(5):564-73. doi: 10.1016/j.bbmt.2009.01.011. Epub 2009 Mar 9.

8.

Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation.

Shulman DS, London WB, Guo D, Duncan CN, Lehmann LE.

Biol Blood Marrow Transplant. 2015 May;21(5):913-9. doi: 10.1016/j.bbmt.2015.01.027. Epub 2015 Feb 7.

9.

Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.

Barba P, Piñana JL, Martino R, Valcárcel D, Amorós A, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.

Biol Blood Marrow Transplant. 2010 Mar;16(3):413-20. doi: 10.1016/j.bbmt.2009.11.008. Epub 2009 Nov 14.

10.

Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates.

Zhang XH, Xu LP, Liu DH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Wang Y, Zhao T, Chen Y, Fu HX, Liu KY, Huang XJ.

Clin Transplant. 2013 Jan-Feb;27(1):80-9. doi: 10.1111/ctr.12000. Epub 2012 Sep 2.

PMID:
22938074
11.

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.

Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, Zhang Y, Liu C, Sun J, Liu Q.

J Hematol Oncol. 2012 Aug 2;5:46. doi: 10.1186/1756-8722-5-46.

12.

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.

George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.

Transpl Infect Dis. 2010 Aug 1;12(4):322-9. doi: 10.1111/j.1399-3062.2010.00504.x. Epub 2010 May 11.

PMID:
20487414
13.

Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.

Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ.

Biol Blood Marrow Transplant. 2009 Sep;15(9):1100-7. doi: 10.1016/j.bbmt.2009.05.010.

14.

Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT).

Bejanyan N, Bolwell BJ, Lazaryan A, Rybicki L, Tench S, Duong H, Andresen S, Sobecks R, Dean R, Pohlman B, Kalaycio M, Copelan EA.

Biol Blood Marrow Transplant. 2012 Jun;18(6):874-80. doi: 10.1016/j.bbmt.2011.10.032. Epub 2011 Oct 29.

15.

Pericardial effusion and cardiac tamponade in pediatric stem cell transplant recipients.

Rhodes M, Lautz T, Kavanaugh-Mchugh A, Manes B, Calder C, Koyama T, Liske M, Parra D, Frangoul H.

Bone Marrow Transplant. 2005 Jul;36(2):139-44.

PMID:
15908968
16.

Engraftment syndrome following allogeneic hematopoietic stem cell transplantation in children.

Nishio N, Yagasaki H, Takahashi Y, Hama A, Muramatsu H, Tanaka M, Yoshida N, Yoshimi A, Kudo K, Ito M, Kojima S.

Pediatr Transplant. 2009 Nov;13(7):831-7. doi: 10.1111/j.1399-3046.2008.01068.x. Epub 2008 Nov 1.

PMID:
19067915
17.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

18.

Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.

Nivison-Smith I, Dodds AJ, Butler J, Bradstock KF, Ma DD, Simpson JM, Szer J.

Biol Blood Marrow Transplant. 2012 Feb;18(2):302-8. doi: 10.1016/j.bbmt.2011.05.003. Epub 2011 May 11.

19.

Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.

Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR.

Bone Marrow Transplant. 2009 Aug;44(3):169-74. doi: 10.1038/bmt.2008.441. Epub 2009 Feb 9.

PMID:
19204709
20.

Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.

Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita-Hoshi Y, Kim SW, Mori S, Heike Y, Makimoto A, Tajima K, Tanosaki R, Tobinai K, Takaue Y.

Biol Blood Marrow Transplant. 2007 Aug;13(8):932-41. Epub 2007 May 29.

Supplemental Content

Support Center